Nonalcoholic fatty liver disease. Other specified inflammatory liver diseases
Conditions
Interventions
Intervention 1: Intervention group: Patients will receive 50000 IU Pearl vitamin D3 once a week for a period of 12 weeks and will also provide recommendations for improving their lifestyle through reg
Treatment - Drugs
Intervention group: Patients will receive 50000 IU Pearl vitamin D3 once a week for a period of 12 weeks and will also provide recommendations for improving their lifestyle through regular exercise an
The control group will receive only lifestyle modification program (regular exercise and diet planning)
Sponsors
Vice Chancellor for research of Qazvin University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion Criteria: Older than 12 years of age; high levels of liver enzymes over the past six months (ALT > 40 U/L); serum vitamin D3 level less than 30 ng/ml; diagnosis to have nonalcoholic fatty liver disease confirmed with sonography results; having non-alcoholic fatty liver disease (NAFLD) and rule out of other hepatic-enzymes rising causes such as viral and autoimmune hepatitis and other chronic liver diseases such as hereditary hemochromatosis, Wilson's disease, an a1- Antitripsin enzyme deficiency; pharmaceutical Hepatitis; consumption of Alcohol. Exclusion Criteria: Pregnancy or lactation; drug abuse; the use of vitamins (multivitamin, vitamin C and vitamin D) in the last 6 months and during the study; weight loss more than 5% during the 6 months before entering the study; diabetes; use of anti-obesity drugs; hypercalcemia; chronic kidney disease; cardio-pulmonary disease; hyperlipidemia which needs medications and Drugs; malignant history; history of the use of effective drugs on the level of ALT such as Valproic acid, Tamoxifen, HMG-COA reductase inhibitors; chemotherapy compounds; Metformin; Statins; Azathioprine; Acetaminophen; antibiotics such as Sulfanamide and Penicillins; Amiodaron; Methotrexate; Isoniazid; Steroids; herbal Medicines; Ursodeoxycholic acid at 3 months before.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hepatic enzymes (aminotransferase). Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Measuring the activity of enzymes in serum. | — |
Secondary
| Measure | Time frame |
|---|---|
| Lipid profiles. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Biochemical method.;Serum level of vitamin D3. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: RadioImmuno Assay method. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Naser Qaeme
Qazvin University of Medical Sciences
Outcome results
None listed